Evaluation of topical human platelet lysate versus topical clobetasol in management of methotrexate-induced oral ulceration in rheumatoid arthritis patients: Randomized-controlled clinical trial

Research Abstract

Ulcers are common symptoms observed in the oral cavity and some ulcerations are induced by drug medications. When ulcers show typical clinical findings diagnosis may be easy, but the management could not be at the same ease. Many kinds of drugs have been reported to cause oral ulcerations. Among them, non-steroidal anti-inflammatory drugs, drugs for the treatment of chronic disorders such as, diabetes, angina pectoris, rheumatoid arthritis, and osteoporosis. Methotrexate (MTX) is a well-established chemotherapeutic agent used for treatment of acute lymphocytic leukemia, lymphomas, choriocarcinoma, and some solid tumours. It is increasingly used in low-dose regimes for a variety of non-neoplastic conditions and its uses and adverse effects are of increasing significance to dentists. Rheumatoid arthritis (RA) is the most common rheumatic disease, and low-dose (5-20 mg per week) methotrexate (MTX) is used extensively as a line of treatment of RA. Low dose MTX has been associated with many toxic effects oral ulceration and mucositis are common adverse effects.

Research Keywords

Human Platelet lysate- Arthritis- oral ulcer- methotrexate- clobetasol propionate